Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.

In adults with overweight or obesity without diabetes in REDEFINE 9, once-weekly cagrilintide-semaglutide 1·7 mg each and 1·0 mg each reduced bodyweight by about 20% at week 68 versus about 2% with placebo.

• Why it matters: Weight loss benefits are established for cagrilintide-semaglutide, but dosing flexibility is needed to support individual tolerability and response in people with obesity-related complications.
• What they did: In this phase 3b, multicentre randomized double-blind trial across 24 sites in Canada, France, Germany, the UK, and the USA, participants received cagrilintide-semaglutide 1·7 mg each or 1·0 mg each versus pooled placebo for 68 weeks, with coprimary endpoints at week 68.
• The result: Both doses significantly outperformed placebo for mean bodyweight change (ETD −18·8 and −19·0 percentage points; p<0·0001) and for achieving ≥5% loss (95·1% and 96·3% vs 33·4%; p<0·0001), with mostly mild-to-moderate gastrointestinal adverse events and no deaths.

AI summary of the abstract · may contain errors · not medical advice · read the paper.